Mandatory medical device diagnostics.
- Transvaginal sonography (ultrasound examination of the genital organs) – for basic diagnostics.
- Renal sonography (ultrasound examination of the kidneys).
- Colposcopy (examination of the vagina and cervix uteri using a special microscope) – for clarification colposcopy in the context of cervical cancer screening or if the tumor is not already macroscopically assessable.
- Fractionated Abrasio (scraping) including hysteroscopy (uterine endoscopy) – in endocervical process.
Optional medical device diagnostics – depending on the results of the history, physical examination, laboratory diagnostics and obligatory medical device diagnostics – for differential diagnostic clarification.
- I.v. pyelogram (radiographic imaging of the urinary organs or urinary tract system) – indicated only in exceptional cases.
- Cystoscopy (urinary bladder endoscopy) – only indicated in exceptional cases of advanced disease.
- Rectoscopy (rectoscopy) – only indicated in exceptional cases of advanced disease.
- X-ray of the thorax (X-ray thorax / chest), in two planes – if necessary in combination with magnetic resonance imaging to primary tumor assessment for staging (staging) on pulmonary metastases (daughter tumors in the lungs).
- Scalenus sonography (ultrasound of the lymph node stations on the neck (M. scalenus)) – from stage Figo IB2 (to exclude distant metastases).
- Computed tomography (CT) of the thorax/chest (thoracic CT) and abdomen (abdominal CT) – to diagnose extrapelvic (“outside the pelvis) spread (all patients from stage IB2.
- Computed tomography (CT) of the pelvis (pelvic CT) or magnetic resonance imaging of the pelvis (pelvic MRI) – if MRI is not possible for local assessment (stage IB1 to IVA); to determine tumor spread.
- FDG* -PET (positron emission tomography) – only in exceptional cases in the recurrent or metastatic situation or in the context of studies.
- Laparoscopy (laparoscopy)/laparatomy (opening of the abdominal cavity) – for surgical staging (staging) from tumor stages greater than stage IA1 with risk factors to stage III.
* Determination of regional glucose metabolism using positron emission tomography (PET) and fluorine-18-labeled fluorodeoxyglucose (FDG) allows detection of metabolic tumor characteristics.
